• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Evolus Announces Appointment of Albert G. White III to Board of Directors

    7/1/24 8:00:00 AM ET
    $COO
    $EOLS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COO alert in real time by email

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee.

    "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aesthetics company to a multi-product performance beauty innovator. His expertise will help Evolus further its strategy and aid in our focus on delivering long-term shareholder value."

    Mr. White commented, "I am honored to join the Evolus Board of Directors at such a pivotal moment in the company's history. The company's flagship product, Jeuveau®, together with its millennial consumer focus and direct-to-consumer digital strategy, is gaining significant traction in the medical aesthetics industry, and its pipeline of filler products will complement the neurotoxin offering."

    Mr. White has served as President & Chief Executive Officer of The Cooper Companies, Inc., branded CooperCompanies (NASDAQ:COO), a leading global medical device company in contact lenses, fertility, and women's health, since May 2018. Previously, he served as Chief Financial Officer from November 2016 until his appointment as CEO and he also served as Executive Vice President and Chief Strategy Officer, positions he held from December 2015 and July 2011, respectively. From August 2015 to May 2018, Mr. White also directed The Cooper Companies, Inc. women's healthcare business and served as Chief Executive Officer of Cooper Medical Inc., the parent company to CooperSurgical. Previously, he served as Vice President, Investor Relations from November 2007 through March 2013 and as Vice President and Treasurer from April 2006 through December 2012. Prior to joining The Cooper Companies, Inc., Mr. White was a Director with KeyBanc Capital Markets for three years and held a number of leadership positions within KeyBank National Association over the prior eight years.

    Following these changes, Evolus' Board of Directors will be composed of seven directors, six of whom are independent.

    About Evolus, Inc.

    Evolus (NASDAQ:EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on  LinkedIn, X, Instagram or Facebook.

    Forward-Looking Statements

    This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical or current facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, or other comparable terms intended to identify statements about the future. The company's forward-looking statements include, but are not limited to, statements related to anticipated product launches; market size, conditions and consumer demand; and the timing of regulatory submissions and approvals.

    The forward-looking statements included herein are based on our current expectations, assumptions, estimates and projections, which we believe to be reasonable, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to, uncertainties associated with our ability to comply with the terms and conditions in the Medytox Settlement Agreements, our ability to fund our future operations or obtain financing to fund our operations, unfavorable global economic conditions and the impact on consumer discretionary spending, uncertainties related to customer and consumer adoption of Jeuveau® and Evolysse™, the efficiency and operability of our digital platform, competition and market dynamics, our ability to successfully launch and commercialize our products in new markets, including the Evolysse™ dermal filler product line in the U.S., our ability to maintain regulatory approvals of Jeuveau® or obtain regulatory approvals for new product candidates or indications, our reliance on Symatese to achieve regulatory approval for the Evolysse™ dermal filler product line in the U.S., and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled "Risk Factors" in our Annual Report on Form 10-K Form and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the Securities and Exchange Commission on May 7, 2024. These filings can be accessed online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If we do update or revise one or more of these statements, investors and others should not conclude that we will make additional updates or corrections.

    Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc.

    Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

    Estyme® is a trademark of Symatese Aesthetics S.A.S.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240701537744/en/

    Get the next $COO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COO
    $EOLS

    CompanyDatePrice TargetRatingAnalyst
    The Cooper Companies Inc.
    $COO
    5/30/2025$76.00Overweight → Neutral
    Analyst
    Evolus Inc.
    $EOLS
    4/17/2025$21.00Buy
    BTIG Research
    The Cooper Companies Inc.
    $COO
    8/29/2024$115.00 → $120.00Overweight
    Piper Sandler
    The Cooper Companies Inc.
    $COO
    7/16/2024$107.00 → $115.00Hold → Buy
    Jefferies
    The Cooper Companies Inc.
    $COO
    3/19/2024$125.00Neutral → Buy
    Redburn Atlantic
    The Cooper Companies Inc.
    $COO
    3/13/2024$100.00 → $120.00Neutral → Overweight
    JP Morgan
    The Cooper Companies Inc.
    $COO
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    Evolus Inc.
    $EOLS
    1/29/2024$10.00 → $16.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $COO
    $EOLS
    Leadership Updates

    Live Leadership Updates

    See more
    • CooperCompanies Appoints Barbara Carbone to Board of Directors

      SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

      4/30/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Evolus Announces Appointment of Albert G. White III to Board of Directors

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

      7/1/24 8:00:00 AM ET
      $COO
      $EOLS
      Ophthalmic Goods
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Nareg will report to Sandra Beaver, Chief Financial Officer of Evolus. "I am thrilled to welcome Nareg to our team," said Sandra Beaver, Chief Financial Officer of Evolus. "Nareg's unique experience will enable him to drive a successful investor relati

      1/4/24 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COO
    $EOLS
    SEC Filings

    See more
    • SEC Form SD filed by The Cooper Companies Inc.

      SD - COOPER COMPANIES, INC. (0000711404) (Filer)

      5/30/25 4:20:18 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by The Cooper Companies Inc.

      10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)

      5/30/25 4:19:23 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 8-K filed by The Cooper Companies Inc.

      8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

      5/29/25 4:31:50 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    $EOLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CooperCompanies Announces Second Quarter 2025 Results

      SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2025. Revenue increased 6% year-over-year to $1,002.3 million. CooperVision (CVI) revenue up 5% to $669.6 million, and CooperSurgical (CSI) revenue up 8% to $332.7 million.GAAP diluted earnings per share (EPS) of $0.44, consistent with last year's second quarter.Non-GAAP diluted EPS of $0.96, up $0.11 or 14% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, CooperCompanies' President and CEO said,

      5/29/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Evolus Announces Departure of its Chief Financial Officer

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has resigned effective June 13, 2025, to accept the same position at a private mental health and wellness technology company. Ms. Beaver's resignation is not a result of any disagreement related to the company's operations, policies or practices, including any accounting principles and practices, or related to any financial statements or disclosures. "On behalf of our employees, our leadership team, and our Board of Directors, I want to thank Sandra for her contributions to Evolus," said David Moatazed

      5/27/25 4:15:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

      Data showed that both Evolysse™ Form and Evolysse™ Smooth met the primary endpoint of non-inferiority1 and demonstrated statistical superiority1 to Restylane®-L, the control product The study published in Aesthetic Surgery Journal supports long-term safety and effectiveness of Cold-X™ crosslinked injectable hyaluronic acid (HA) gels for the correction of dynamic facial wrinkles and folds Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of the U.S. pivotal study results for Evolysse™ Form and Evolysse™ Smooth in the Aesthetic Surgery Journal, a leading peer-reviewed journal focusi

      5/22/25 8:00:00 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COO
    $EOLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $COO
    $EOLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Officer Avelar Rui sold $33,397 worth of shares (3,385 units at $9.87), decreasing direct ownership by 0.93% to 359,082 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      5/14/25 7:27:50 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Beaver Sandra sold $65,070 worth of shares (6,494 units at $10.02), decreasing direct ownership by 4% to 167,089 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      5/14/25 7:27:40 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Moatazedi David sold $155,756 worth of shares (15,787 units at $9.87), decreasing direct ownership by 3% to 492,832 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      5/14/25 7:27:28 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cooper downgraded by Analyst with a new price target

      Analyst downgraded Cooper from Overweight to Neutral and set a new price target of $76.00

      5/30/25 8:39:00 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • BTIG Research initiated coverage on Evolus with a new price target

      BTIG Research initiated coverage of Evolus with a rating of Buy and set a new price target of $21.00

      4/17/25 8:32:06 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler reiterated coverage on Cooper with a new price target

      Piper Sandler reiterated coverage of Cooper with a rating of Overweight and set a new price target of $120.00 from $115.00 previously

      8/29/24 8:24:13 AM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    $EOLS
    Financials

    Live finance-specific insights

    See more
    • CooperCompanies Announces Second Quarter 2025 Results

      SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2025. Revenue increased 6% year-over-year to $1,002.3 million. CooperVision (CVI) revenue up 5% to $669.6 million, and CooperSurgical (CSI) revenue up 8% to $332.7 million.GAAP diluted earnings per share (EPS) of $0.44, consistent with last year's second quarter.Non-GAAP diluted EPS of $0.96, up $0.11 or 14% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, CooperCompanies' President and CEO said,

      5/29/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Evolus Reports First Quarter 2025 Results

      Global Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Achieving Positive Non-GAAP Operating Income on a Consolidated Basis for the Full-Year 2025 Evolysse™ Launched in Q2 and Off to a Strong Start Reaffirms 2025 Net Revenue Guidance of $345 Million to $355 Million; Evolysse™ and Estyme® Injectable Hyaluronic Acid (HA) Gels Anticipated to Contribute 8 to 10% of Total Revenue for the Full-Year 2025 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a

      5/7/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CooperCompanies Announces Release Date for Second Quarter 2025

       SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1515103. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful

      4/29/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    $EOLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Evolus Inc.

      SC 13G/A - Evolus, Inc. (0001570562) (Subject)

      11/14/24 4:50:28 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evolus Inc.

      SC 13G/A - Evolus, Inc. (0001570562) (Subject)

      11/14/24 4:00:06 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evolus Inc.

      SC 13G/A - Evolus, Inc. (0001570562) (Subject)

      11/13/24 5:38:05 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care